It’s only fair to share… FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis 05/17/2017 04:14 PM EDT The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, …